Autonomix Medical (NASDAQ:AMIX) Stock Rating Upgraded by Wall Street Zen

Autonomix Medical (NASDAQ:AMIX) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Sunday, Wall Street Zen reports.

A number of other research firms have also issued reports on AMIX. Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Zacks Research raised shares of Autonomix Medical to a “hold” rating in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $42.00.

Autonomix Medical Stock Performance

NASDAQ:AMIX opened at $4.59 on Friday. The firm has a market capitalization of $4.45 million, a price-to-earnings ratio of -0.11 and a beta of -1.00. Autonomix Medical has a 1-year low of $2.44 and a 1-year high of $32.55. The business’s fifty day moving average price is $6.08 and its 200 day moving average price is $7.40.

Autonomix Medical (NASDAQ:AMIX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) EPS for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. Equities analysts forecast that Autonomix Medical will post -20.17 earnings per share for the current year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.